MedTrace Logo

Composition for Treating Cirrhosis and Liver Cancer (SB-1121)

NCT05178303 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2025-05-16

No results posted yet for this study

Summary

The composition treats cirrhosis and hepatocellular carcinoma (Hcc) at an early stage. The product is extracted from herbs, including Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Ascorbic acid, pyridoxine 5-phosphate, L-Arginine hydrochloride, Pregnenolone acetate. These components have participated in repairing and regenerating new liver parenchyma, preventing fibrosis cell generation, preventing liver cancer cell growth at an early stage. The composition supplements precursors which help the body strengthen antibodies and reduce the risk of inflammation, restore physiological and biochemical functions of liver cells after chronic inflammation.

Conditions

  • Cirrhosis of the Liver

Interventions

DRUG

SB-1121(1)

The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.

DRUG

SB-1121(2)

The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.

Sponsors & Collaborators

  • Tran Minh Duc

    collaborator UNKNOWN

  • Nguyen Thi Trieu, MD

    lead INDIV

Principal Investigators

  • Tran Minh Cam Tu, Dr. · Saigon Biopharma Company Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2021-10-10
Completion
2021-11-10
FDA Drug
Yes

Countries

  • United States
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05178303 on ClinicalTrials.gov